Second, this analysis focused exclusively on a subset of GLP-1 RA therapies (specifically semaglutide and tirzepatide) and did not account for other common PCOS treatments, such as metformin, combined oral contraceptives, or anti-androgen therapies
Finally, we discuss health inequities in obesity, the dangers of perpetuating these inequities if GLP-1RA access remains biased, and the opportunities for improvement [46]
Researchers need to see whether the dysesthesia rate holds at approximately 20.9% for the 12mg dose across all populations, or whether certain groups are more or less susceptible
Instead of trying to develop things that people would crave, it shifts to food product guidance that is about tolerance, avoiding displeasures, or slowing down eating rates through textural design, Lundahl says
This is the medication beginning to establish its effects
easily reconstituted for research applications